Literature DB >> 16223971

Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report.

Nunzio Pomara1, Lisa M Willoughby, John J Sidtis, Pankaj D Mehta.   

Abstract

OBJECTIVE: Longitudinal changes in plasma beta amyloid protein 1-42 and 1-40 (Abeta42 and Abeta40) levels and possible relationships with cognitive decline and apolipoprotein (APOE) genotype were studied in healthy elderly individuals.
METHODS: Authors determined cognitive level and plasma Abeta40 and Abeta42 levels twice, approximately 4 years apart, in 34 elderly subjects.
RESULTS: Analyses revealed a selective reduction in Abeta42 levels at follow-up, which were not modulated by the epsilon4 allele. Greater reductions and higher baseline plasma Abeta42 levels were associated with reductions in cognitive scores.
CONCLUSIONS: Alterations in plasma Abeta42 levels may be associated with subtle cognitive decline in elderly subjects without dementia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223971     DOI: 10.1176/appi.ajgp.13.10.914

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  36 in total

Review 1.  Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants.

Authors:  Richard Mayeux; Nicole Schupf
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Toward a plasma marker for Alzheimer disease: some progress, but still a long way to go.

Authors:  Howard A Crystal; Peter Davies
Journal:  Neurology       Date:  2008-02-19       Impact factor: 9.910

3.  Soluble amyloid-β levels and late-life depression.

Authors:  Ricardo S Osorio; Tyler Gumb; Nunzio Pomara
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

4.  Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.

Authors:  N Schupf; W B Zigman; M-X Tang; D Pang; R Mayeux; P Mehta; W Silverman
Journal:  Neurology       Date:  2010-11-02       Impact factor: 9.910

Review 5.  Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Authors:  Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow
Journal:  Exp Neurol       Date:  2009-10-06       Impact factor: 5.330

Review 6.  Current understanding of the neurobiology and longitudinal course of geriatric depression.

Authors:  Sara L Weisenbach; Anand Kumar
Journal:  Curr Psychiatry Rep       Date:  2014-09       Impact factor: 5.285

Review 7.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

8.  Elevation in plasma Abeta42 in geriatric depression: a pilot study.

Authors:  Nunzio Pomara; P Murali Doraiswamy; Lisa M Willoughby; Amy E Roth; Benoit H Mulsant; John J Sidtis; Pankaj D Mehta; Charles F Reynolds; Bruce G Pollock
Journal:  Neurochem Res       Date:  2006-04-01       Impact factor: 3.996

9.  Amyloid-associated depression: a prodromal depression of Alzheimer disease?

Authors:  Xiaoyan Sun; David C Steffens; Rhoda Au; Marshal Folstein; Paul Summergrad; Jacqueline Yee; Irwin Rosenberg; D Mkaya Mwamburi; Wei Qiao Qiu
Journal:  Arch Gen Psychiatry       Date:  2008-05

10.  Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.

Authors:  V P Prasher; S G Sajith; P Mehta; W B Zigman; N Schupf
Journal:  Int J Geriatr Psychiatry       Date:  2010-02       Impact factor: 3.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.